Ask about this productRelated genes to: TPMT antibody
- Gene:
- TPMT NIH gene
- Name:
- thiopurine S-methyltransferase
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 6p22.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-08-25
- Date modifiied:
- 2019-04-23
Related products to: TPMT antibody
Related articles to: TPMT antibody
- Pharmacogenetics plays an increasingly important role in oncology by supporting individualized therapeutic strategies based on patient genetic profiles. ClinicalTrials.gov provides a valuable platform for evaluating global trends in pharmacogenetic anticancer clinical trials. This systematic review aimed to evaluate pharmacogenetic-focused anticancer clinical trials registered on ClinicalTrials.gov and summarize trends in study design, cancer types, targeted biomarkers, therapeutic interventions, and geographic distribution. - Source: PubMed
Ashour Ahmed MAlhayyan AliahAlhayyan Rawan - Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited diagnostic tools and therapeutic options. Dysregulated mitophagy in astrocytes plays a pivotal role in AD pathogenesis. This study aims to identify a mitophagy and astrocyte (MA)-associated molecular signature for AD diagnosis and therapeutic targeting. - Source: PubMed
Publication date: 2026/07/24
Liu JiachengChen Wei - The Clinical Pharmacogenetics Implementation Consortium (CPIC) TPMT/NUDT15 Pharmacogene Curation Expert Panel (PCEP) conducted a comprehensive review of clinical, laboratory, and computational evidence to determine the clinical function assignments for TPMT and NUDT15 star alleles. These genes are critical for the metabolism of thiopurines, which are widely used in the treatment of cancer and autoimmune disorders. Standardized allele function assignment is essential for predicting metabolizer phenotypes and pharmacogenetics-guided thiopurine dosing. The work presented here includes the first designation of decreased function alleles for both TPMT and NUDT15, reflecting new clinical data that demonstrate partial loss of enzymatic activity and reduced dose tolerance. The panel also reclassified several alleles previously assigned uncertain or unknown function. The functional assignments were informed by a standardized framework incorporating clinical data, such as thiopurine tolerance and toxicity, as well as in vitro protein activity, ex vivo enzymatic measurements, and in silico variant effect prediction tools. These updates enhance the precision of genotype-to-phenotype mapping and support more personalized thiopurine therapy across diverse patient populations. - Source: PubMed
Publication date: 2026/08/06
Tibben Bailey MMaillard MaudPratt Victoria MMoyer Ann MFigueroa Debbie MWhirl-Carrillo MichelleGaedigk AndreaStocco GabrieleSchwab MatthiasCaudle Kelly EYang Jun J - Interpatient variability in chemotherapy response and toxicity remains a major challenge in oncology. Pharmacogenomics (PGx) is an approach to address this challenge by combining somatic alterations that affect tumour sensitivity with germline variants that affect drug metabolism, transport and toxicity. This review provides a critical evaluation of clinically validated PGx biomarkers for chemotherapeutics and targeted therapy with a focus on translational relevance and strength of evidence. High-impact germline markers such as DPYD, TPMT, NUDT15 and UGT1A1 are highlighted as key determinants of genotype-guided dosing for improving safety without compromising efficacy. Somatic biomarkers such as EGFR, RAS, BRAF, and HER2 remain central to treatment selection, while resistance underscores the need for ongoing molecular assessment. A tiered implementation framework, barriers to progress, and future directions involving polygenic models, multi-omics, and artificial intelligence (AI) are discussed to advance safe, effective, and personalized chemotherapy. - Source: PubMed
Publication date: 2026/08/06
Vishwash Satyam KumarSoni Ram BabuKosey SourabhSood Ratima - Chemotherapy-related toxicities remain a major barrier to optimal outcomes in pediatric cancer care in low-resource settings. Genetic variation in drug-metabolizing and transport pathways contributes to interindividual differences in toxicity risk; however, pharmacogenomic data from African pediatric populations are limited. This study assessed the distribution of selected pharmacogenomic variants and chemotherapy-related toxicities profiles in Tanzanian children with cancer. - Source: PubMed
Publication date: 2026/07/20
Katabalo Deogratias MFundo BarakaMinja Winfrida VKashaigiri Heronima JoasMwita StanleyLiwa Anthony CuthbertSchroeder KristinKidenya Benson R